Dear Healthcare Provider,
We are currently in the respiratory syncytial virus (RSV) season and would like to provide important guidance regarding the administration of RSV immunization for both pregnant women and newborns to ensure optimal protection during this critical period.
Guidance for Pregnant Patients
The Kentucky Department for Public Health recommends maternal RSV vaccination during pregnancy at 32 0/7 through 36 6/7 weeks of gestation to provide passive immunity to newborns during RSV season. Abrysvo (Pfizer) is the only RSV vaccine approved for use during pregnancy and should be administered within this gestational window. Maternal RSV vaccination will conclude on January 31, 2026, for the 2025–2026 RSV season. If your patient is 32 0/7–36 6/7 weeks in January 2026, vaccination should occur no later than January 31, 2026.
For more details, please visit the American College of Obstetricians and Gynecologists’ official guidance for pregnant individuals: Maternal Respiratory Syncytial Virus Vaccination
Guidance for Newborns
For Kentucky, the administration of RSV monoclonal antibody products to newborns and infants will end on March 31, 2026. It will resume on October 1, 2026, at the start of the RSV season.
If an infant is born before March 31, 2026, and the mother did not receive the RSV vaccine during pregnancy, it is recommended that the infant receive a long-acting monoclonal antibody within one week of birth to provide direct protection during their first RSV season such as Beyfortus (nirsevimab) or Enflonsia (clesrovimab).
We urge healthcare providers to adhere to these guidelines to help protect infants from severe RSV-related illness and hospitalization. For further information and official clinical guidance, please visit the AAP's Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement
Thank you,
Chad C. Eldridge, DNP, RN, CIC
Immunization Branch Manager
Kentucky Department for Public Health
